Innovative Therapeutics in Oncology and Neuroscience
1 VYVGART Initial Progress Encouraging; Laying Foundation for Strong Growth
2023
Jun
30
Sep
5
2024
Jan
1
VYVGART
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial
Ⓡ
9
China NDA
Approved
1st Dispatched &
NRDL Included
1st Prescription
Strong Launch in Q4'23
✓ Top 200 target hospitals reached in-person by medical
representatives¹
✓ Nearly all top 100 HCPs have already prescribed VYVGART1
✓ Brand awareness significantly boosted in Dec'23
through 4 months' marketing campaign
72% of HCPs surveyed are aware of VYVGART (up from
54%)²
Nearly 1,000 est. patients treated (Sep'23 through Dec'23)
•
Jan'24 Progress and Next Steps
✓ Nearly 1,000 est. new patients treated in Jan 24 alone
Drive awareness and adoption
Expand outreach to ~1,000 hospitals in 2024, accounting for
>80% of total patient volume
Dedicated sales representatives ~150 post-NRDL
Upcoming potential regulatory actions in China
Efgartigimod SC in gMG under regulatory review
Submission of sBLA in CIDP in 1H'24
Abbreviation: Healthcare professional (HCP).
Notes: (1) As of December 31, 2023; (2) Based on a survey of 250 physicians, awareness of VYVGART rose from 54% to 72%.
Sources: Expert Interview, BenHealth Consulting research and analysis, January 2024.
zajǝbView entire presentation